-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 1, 2021, Cinda Biotech and Baoyuan Pharmaceutical jointly announced that the two parties have reached an agreement under which Cinda Bio and Baoyuan Pharmaceutical will jointly develop and commercialize Baoyuan Pharmaceutical's main drug candidate Taletrectinib in Greater China.
According to the terms of the agreement, Cinda Bio will obtain the right to jointly develop and commercialize Ttaletrectinib in the Greater China Region with Baoyuan Pharmaceutical as an exclusive partner.
Baoyuan Pharmaceutical will continue to be responsible for the clinical development and registration of Taletrectinib in mainland China, as well as clinical production and commercial production in Greater China.
Cinda Biotech has the right to jointly develop Taletrectinib and be responsible for registration and approval in Hong Kong, Macau and Taiwan.
According to the agreement, Baoyuan Pharmaceutical will receive a total of up to 189 million U.
S.
dollars in advance payment and development cost funding and potential milestone payments, as well as royalties based on Taletrectinib's annual net sales in Greater China.
Taletrectinib is a next-generation tyrosine kinase inhibitor targeting ROS1 and NTRK.
It is currently undergoing three phase II clinical trials, including one in China for initial treatment of first-line TKI and ROS1 positive for second-line TKI treatment.
Phase II clinical trial for non-small cell lung cancer, a phase II clinical trial for NTRK-positive solid tumors in China, and a second-line clinical trial for first-line and second-line ROS1-positive non-small cell lung cancer in the world.
Phase clinical trials.
As of January 15, 2021, an ongoing Phase II clinical trial of Taletrectinib (TRUST) showed that among 11 patients with advanced ROS1-positive non-small cell lung cancer who were not treated with ROS1 TKI, the ORR judged by the investigator was 100% ; At the same time Taletrectinib shows good safety.
These data indicate that Taletrectinib may become best-in-class.
More data on Taletrectinib's first-line (ROS1 TKI initial treatment) and second-line (ROS1 TKI treatment) treatment of ROS1-positive non-small cell lung cancer will be published at the 2021 ASCO meeting.
End reference materials: [1] Cinda Bio's official website selected in the past to watch the Cell Breakthrough: The foodies are moved and cry! Scientists have found a new fat-burning pathway with the potential for long-lasting effect.
Finally! Sinopharm officially announced the Phase 3 clinical data of two new crown inactivated vaccines, both of which are more than 70% effective in preventing COVID-19.
Scientists from Peking University publish the top issue of Cell: Using spliceosome inhibitors to produce all-round stem cells in mice.
The world's "popular fried chicken"! New research reveals: Nicotinamide can also regulate retinal function, effectively improve glaucoma craze and write a new legend in gene therapy.
Optogenetic therapy has revived blind people who have been blind for 40 years for the first time.
Drug Targets| Healthy Life| Pharmaceutical News| Drug Inventory| Pharmaceutical Technology| Fundamental Research on Drug Side Effects/ Translational Medicine Leukemia| Lung Cancer| Gastric Cancer| Colorectal Cancer| Liver Cancer| Breast Cancer| Pancreatic Cancer| Cardiovascular Disease| Neurodegenerative Diseases | Intestinal microbial medical devices/biotechnological in vitro diagnostics | Medical devices | Bio-nano | 3D printing | Genetic testing | Single cell sequencing | Gene editing | Assisted reproduction | Artificial intelligence | Precision medicine policy anti-cancer drugs | 4+7 volume procurement | Consumables | Filing System | Registrant System | Healthy China | New Edition of Essential Medicines Directory | AI Medical Devices | Telemedicine | Same Equity Different Equity Market/Capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | ChiNext | R&D Investment | Acquisitions | Market & Consumption
According to the terms of the agreement, Cinda Bio will obtain the right to jointly develop and commercialize Ttaletrectinib in the Greater China Region with Baoyuan Pharmaceutical as an exclusive partner.
Baoyuan Pharmaceutical will continue to be responsible for the clinical development and registration of Taletrectinib in mainland China, as well as clinical production and commercial production in Greater China.
Cinda Biotech has the right to jointly develop Taletrectinib and be responsible for registration and approval in Hong Kong, Macau and Taiwan.
According to the agreement, Baoyuan Pharmaceutical will receive a total of up to 189 million U.
S.
dollars in advance payment and development cost funding and potential milestone payments, as well as royalties based on Taletrectinib's annual net sales in Greater China.
Taletrectinib is a next-generation tyrosine kinase inhibitor targeting ROS1 and NTRK.
It is currently undergoing three phase II clinical trials, including one in China for initial treatment of first-line TKI and ROS1 positive for second-line TKI treatment.
Phase II clinical trial for non-small cell lung cancer, a phase II clinical trial for NTRK-positive solid tumors in China, and a second-line clinical trial for first-line and second-line ROS1-positive non-small cell lung cancer in the world.
Phase clinical trials.
As of January 15, 2021, an ongoing Phase II clinical trial of Taletrectinib (TRUST) showed that among 11 patients with advanced ROS1-positive non-small cell lung cancer who were not treated with ROS1 TKI, the ORR judged by the investigator was 100% ; At the same time Taletrectinib shows good safety.
These data indicate that Taletrectinib may become best-in-class.
More data on Taletrectinib's first-line (ROS1 TKI initial treatment) and second-line (ROS1 TKI treatment) treatment of ROS1-positive non-small cell lung cancer will be published at the 2021 ASCO meeting.
End reference materials: [1] Cinda Bio's official website selected in the past to watch the Cell Breakthrough: The foodies are moved and cry! Scientists have found a new fat-burning pathway with the potential for long-lasting effect.
Finally! Sinopharm officially announced the Phase 3 clinical data of two new crown inactivated vaccines, both of which are more than 70% effective in preventing COVID-19.
Scientists from Peking University publish the top issue of Cell: Using spliceosome inhibitors to produce all-round stem cells in mice.
The world's "popular fried chicken"! New research reveals: Nicotinamide can also regulate retinal function, effectively improve glaucoma craze and write a new legend in gene therapy.
Optogenetic therapy has revived blind people who have been blind for 40 years for the first time.
Drug Targets| Healthy Life| Pharmaceutical News| Drug Inventory| Pharmaceutical Technology| Fundamental Research on Drug Side Effects/ Translational Medicine Leukemia| Lung Cancer| Gastric Cancer| Colorectal Cancer| Liver Cancer| Breast Cancer| Pancreatic Cancer| Cardiovascular Disease| Neurodegenerative Diseases | Intestinal microbial medical devices/biotechnological in vitro diagnostics | Medical devices | Bio-nano | 3D printing | Genetic testing | Single cell sequencing | Gene editing | Assisted reproduction | Artificial intelligence | Precision medicine policy anti-cancer drugs | 4+7 volume procurement | Consumables | Filing System | Registrant System | Healthy China | New Edition of Essential Medicines Directory | AI Medical Devices | Telemedicine | Same Equity Different Equity Market/Capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | ChiNext | R&D Investment | Acquisitions | Market & Consumption
